

# Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma

WENMIN HOU<sup>1,2\*</sup>, JIBIN LIU<sup>2,3\*</sup>, PEIZHAN CHEN<sup>2</sup>, HUI WANG<sup>2</sup>, BANG-CE YE<sup>1</sup> and FULIN QIANG<sup>3</sup>

<sup>1</sup>Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237; <sup>2</sup>Key Laboratory of Food Safety Research, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031; <sup>3</sup>Tumor Institute, Nantong Tumor Hospital, Nantong, Jiangsu 226000, P.R. China

Received November 30, 2013; Accepted April 4, 2014

DOI: 10.3892/ol.2014.2253

**Abstract.** The RAS/RAF and PI3K/PTEN signaling pathways play central roles in hepatocarcinogenesis. *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* are key cancer-related genes in the RAS/RAF and PI3K/PTEN signaling pathways. Genetic alterations in these genes often lead to the dysregulation of the two cascades. Little is known regarding the frequency of hotspot mutations in these critical components among Chinese patients with hepatocellular carcinoma (HCC). In the current study, 57 somatic hotspot mutations in 36 HCCs samples collected from Chinese patients using direct DNA sequencing method were examined. Two cases of *KRAS* somatic mutations (*KRAS* codon 61; Gln to His) were identified among 36 HCCs (5.6%). However, no mutations were found in the *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes. These findings indicated that point mutations in the *KRAS* gene, but not mutations in *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes, at a somatic level contribute to the abnormal activation of the RAS/RAF and PI3K/PTEN pathways in HCC.

## Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for >740,000 new cases

and 690,000 mortalities per year (1). Half of these new cases and mortalities were estimated to occur in China. The high rates of HCC in China are largely due to the prevalence of chronic hepatitis B virus (HBV) infection (2). The RAS/RAF and PI3K/PTEN signaling pathways play central roles in hepatocarcinogenesis (3). The aberrant activation of the RAS/RAF and PI3K/PTEN signaling pathways is associated with poor prognosis in cancer patients (4,5). HBV also utilizes the pathways for the control of hepatocyte survival and viral replication (6,7). Mutations of key components (such as *RAS*, *RAF*, *PIK3CA*, *PIK3R1* and *PTEN*) in the RAS/RAF and PI3K/PTEN pathways lead to the dysregulation of the two cascades (8). The *RAS* family comprises three members: *KRAS*, *NRAS* and *HRAS*. Somatic mutations in the *RAS* family are common in numerous human cancer types, including pancreatic, thyroid, colorectal, liver, kidney and lung (9). *BRAF* is the most frequently mutated gene in the *RAF* family, and the *BRAF* mutation has been reported in 61% of melanoma, 53% of papillary thyroid cancer and 11.5% of colorectal cancer patients (10-12). The *PI3K* gene comprises *PIK3CA*, which encodes the catalytically active p110 $\alpha$  subunit, and *PIK3R1*, encoding the p85 $\alpha$  regulatory subunit (13). *PIK3CA* is mutated in numerous tumor types, with the frequency ranging from 4 to 32% in breast, colorectal, endometrial, brain, gastric and lung cancer (14-17). *PIK3R1* mutations were identified in 43% of endometrial cancer, 4% of ovarian cancer and 2% of colon cancer (18-19). *PTEN* acts as a negative regulator of the PI3K pathway and *PTEN* mutations lead to a reduction of its phosphatase activity (20). Mutations of the *PTEN* gene are associated with a wide variety of human tumors (21).

Inhibitors targeting the RAS/RAF and PI3K/PTEN pathways have been developed and the clinical responses of patients were observed to differ according to the genetic alterations of the critical components of the two cascades (22). However, few data are available regarding the prevalence of *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* mutations in Chinese patients with HCC. In the present study, we conducted mutational analysis of 57 somatic hotspot mutations in *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* in 36 Chinese patients with HCC.

**Correspondence to:** Professor Fulin Qiang, Tumor Institute, Nantong Tumor Hospital, 30 Tongyang Beilu, Nantong, Jiangsu 226000, P.R. China  
E-mail: nantongflqiang@gmail.com

Professor Bang-Ce Ye, Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 120 Meilong Road, Shanghai 200237, P.R. China  
E-mail: bcye@ecust.edu.cn

\*Contributed equally

**Key words:** hepatocellular carcinoma, mutation analysis, *KRAS*, cancer-related genes

Table I. Primers used for polymerase chain reaction in this study.

Gene	Mutation	Forward primer sequence (5' to 3')	Reverse primer sequence (5' to 3')
KRAS	G12C, G12D, G13S, G13D, L19F, Q22K A59T, Q61E, Q61R, Q61H A146T	CTTAAGCGTCGATGGAGGAG	CCCTGACATACTCCCAAGGA
		GGTGCTTAGTGGCCATTGT	CCTAGGTTTCAATCCCAGCA
		TTGTGGACAGGTTTGTGAAAGA	AGAAACCAAAAGCCAAAAGCA
NRAS	G12S, G12V, G13R, G13V, A18T Q61K, Q61R, Q61H	GCCCAAGGACTGTTGAAAAA	CCGACAAGTGAGAGACAGGA
		GGCAGAAATGGGCTTGAATA	AGTTAATATCCGCAATGAC
HRAS	G12S, G12V, G13R, G13D Q61K, Q61R, Q61H	GTGGGTTTGCCCTTCAGAT	TGGTGATGTCCTCAAAAGA
		TGGCTGTGTGAACCTCCC	GTCAGTGAGTGCTGCTCCC
BRAF	G464V, G466V, G469A, V471F D594G, L597V, V600E	CACTTGGTAGACGGGACTCG	AGTTTATTGATGCGAACAGTGA
		AACTCTTCATAATGCTTGCTCTGA	AGCCTCAATTCTTACCATCCA
		GCCTAATCAAGTCAAACTATGGAA	AAGCTTTATGGTTATTTGCATTTT
PIK3CA	R38G, Q75E, R108H G118D C378R C420R	ATGTTTGCTGCCCTTTGCTCT	ATAAGCAGTCCCTGCCCTTCA
		TAAGGGGATTGTGGGCCTAT	AATGGGGTCTTGCTTTTGTG
		CTCATGCTTGCTTTGGTTCA	TTGGCATGCTCTTCAATCAC
		GATTGGTCTTTTCCCTGTCTCTG	CCACAAATATCAATTACAAACCAATTG
		CATTTGCTCCCAAACTGACCA	CACCCCAAGCATTTTCTTC
		CAGACGGGACCTTTTGGTA	AACAAAATAGCTGACATGGAACA
PIK3R1	P539R, E542K, E545K, E545G, Q546K T1025A, M1043T, M1043I, H1047Y, H1047R, H1047L	GGCTTCTCTGACCCATTAAACC	CCCCACCTCATTCGTAAAAA
		GGAAGAGAAGCCACGCTTAA	CCCAACCACTCGTTCAACTT
		CCGTATAGCGTAAATTCCCAGA	TCTCAGATCCAGGAAGAGGAA
PTEN	R130G, R130Q R233X	TGCTTGAGATCAAGATTGCAG	GCCATAAGGCCCTTTTCCTTC

## Materials and methods

**Patients and tissue samples.** Thirty-six patients with HCC undergoing surgery at Nantong Tumor Hospital (Nantong, China) between 2009 and 2011 were enrolled in this study. Tumor samples and adjacent normal liver tissues from the corresponding patients were fixed with 10% formalin, embedded in paraffin and stained with hematoxylin and eosin (H&E). Tumor staging was performed according to the Barcelona Clinic Liver Cancer (BCLC) staging classification (23). This study was approved by the Ethics Committee of Nantong Tumor Hospital. Written informed consent was obtained from each patient prior to sample collection.

**Genomic DNA extraction.** Tumor areas and non-tumorous tissue areas were identified on H&E-stained slides. Genomic DNA was extracted from formalin-fixed paraffin-embedded tissues of HCC with the QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. Briefly, samples were placed into Eppendorf tubes and the paraffin was removed. Next, the tubes were incubated with proteinase K (Qiagen GmbH) at 56°C for 1 h. Following proteinase K digestion, the samples were incubated at 90°C for 1 h and DNA was extracted using QIAamp MinElute columns (Qiagen GmbH).

**Mutation analysis.** Polymerase chain reaction (PCR) was performed to amplify the gene fragments including the hotspot mutations shown in Table I. The selection of the hotspots was based on the prevalence of mutations in cancers identified in the COSMIC database (24). A 50 µl volume of PCR was prepared using the Taq PCR Master Mix kit (Qiagen GmbH), according to the manufacturer's instructions. The thermocycling was performed at 94°C for 3 min; 35 cycles of 94°C for 30 sec, 56°C for 30 sec and 72°C for 60 sec; followed by a final 10 min at 72°C. PCR products were run on 1.5% agarose gel electrophoresis and visualized with ultraviolet light to confirm sizes. DNA purification was performed with the QIAprep Gel Extraction kit (Qiagen GmbH) according to the manufacturer's instructions. Briefly, the DNA fragments were excised from the agarose gel with a scalpel and placed in a colorless tube. DNA cleanup was conducted using QIAquick spin columns (Qiagen GmbH). Direct DNA sequencing was performed using a Big Dye Terminator (v3.1) kit (Applied Biosystems, Foster City, CA, USA). The sequencing products were run on an Applied Biosystems 3130XL Genetic Analyzer (Applied Biosystems). DNA sequencing results were analyzed using Chromas software (Technelysium, Brisbane, Queensland, Australia). The primers used for the PCR are listed in Table I.

## Results

**Clinicopathological characteristics.** Of 36 patients with HCC, the median age was 54 years (range, 40-77 years), including 33 males and three females. The majority of the cases had HCC associated with HBV infection (34/36; 94.4%). All patients were negative in hepatitis C virus infection. The concentrations of serum AFP of 16 patients (16/36; 44.4%) were higher than 400 ng/ml. The BCLC staging classification was used to

Table II. Clinical characteristics of hepatocellular carcinoma patients.

Characteristic	Value
Age, years	
Median (range)	54 (40-77)
Gender, n (%)	
Male	33 (91.7)
Female	3 (8.3)
Etiology, n (%)	
HBV(+)	34 (94.4)
HBV(-)	2 (5.6)
AFP, n (%)	
>400 ng/ml	16 (44.4)
≤400 ng/ml	20 (55.6)
Stage, n (%)	
0	2 (5.6)
A	25 (69.4)
B	8 (22.2)
C	1 (2.8)
D	0 (0.0)

classify the cancer staging (23). There were 2, 25, 8, 1 and 0 cases of stages 0 to D, respectively (Table II).

**Mutation analysis of key genes in the RAS/RAF and PI3K/PTEN pathways.** We analyzed hotspot-containing gene fragments of key genes in RAS/RAF and PI3K/PTEN pathways using PCR amplification followed by direct sequencing. The hotspots were listed in Table I. In all, two samples (Sample #13 and #35) had point mutations in codon 61 (Q61H) of the *KRAS* gene and the mutation rate was 5.6% (Fig. 1). In the two cases, codon 61 was altered from CAA, coding for Gln, to CAC, coding for His. To confirm the two mutations occurred at the somatic level, we tested codon 61 mutation status in non-tumorous tissues from the two patients. The results showed that codon 61 was wild-type in normal tissues from Sample #13 and #35 (Fig. 1). The two patients harboring *KRAS* mutation were male. Patient no. 13 was 49 years old, had HBV infection and stage A HCC, and an AFP level of 3.4 ng/ml. Patient no. 35 was 69 years old, had stage B HCC and was negative for HBV infection, with an AFP level of 1.95 ng/ml. No other mutations in the *HRAS*, *NRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes were identified.

## Discussion

Targeting the RAS/RAF and PI3K/PTEN pathways are novel therapeutic strategies that may be exploited for the treatment of HCC (8). As the RAF-kinase inhibitor sorafenib has been demonstrated to be effective in the treatment of HCC, *BRAF* mutations have become a favored target in HCC treatment recently (25). However, the somatic mutation prevalence and distribution of the key genes in the two pathways remain largely unknown in Chinese patients with HCC. Therefore, the present

Table III. Reported point mutations in codons 12, 13, and 61 of *KRAS* in hepatocellular carcinomas.

Author (ref)	Population	No. of patients	Codon 12	Codon 13	Codon 61	Frequency (%)
Zuo <i>et al</i> (36)	Chinese	64	2	1	NA	4.7
Huang <i>et al</i> (31)	Chinese	10	0	0	0	0.0
Taketomi <i>et al</i> (33)	Japanese	61	0	1	0	1.6
Tsuda <i>et al</i> (43)	Japanese	30	1	0	0	3.3
Taniguchi <i>et al</i> (44)	Japanese	15	0	0	NA	0.0
Fujimoto <i>et al</i> (29)	Japanese	27	0	0	0	0.0
Tada <i>et al</i> (45)	Japanese	12	0	0	0	0.0
Bose <i>et al</i> (46)	Indian	30	2	0	0	6.7
Tannapfel <i>et al</i> (27)	German	25	0	0	NA	0.0
Weihrach <i>et al</i> (47)	German	20	3	0	NA	15.0
Challen <i>et al</i> (32)	British	19	0	NA	1	5.3
Guichard <i>et al</i> (30)	French	149	1	0	1	1.3
Colombino <i>et al</i> (37)	Italian	65	1	0	0	1.5

NA, not available.




Figure 1. Sequence analysis of *KRAS* gene mutation in codon 61 in two hepatocellular carcinoma cases. Sequence chromatograms of codon 61 in tumor and normal tissues from (A) Sample #13 and (B) Sample #35.

study set out to examine the frequency of hotspot mutations of the *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes in 36 human HCC tissues from Chinese patients. Only *KRAS* somatic mutations were identified, with a mutation rate of 5.6%.

The incidence of *KRAS* mutations has been found in 80% of advanced pancreatic cancer (26), 45% of cholangiocarcinoma (27) and 32% of colorectal cancer (28) patients. COSMIC

database has shown that mutations in codons 12, 13 and 61 of the *KRAS* gene are known hotspots in various types of cancer. The frequency and distribution of *KRAS* mutation in HCC from several previous studies are summarized in Table III. The majority of these studies have shown that *KRAS* gene mutations occur infrequently (<10%) in HCC. The codon 12 accounts for the majority of *KRAS* mutations detected (~70%), whereas mutations affecting codon 13 and codon 61 account for the remaining

30%. One third of the twelve studies did not evaluate the *KRAS* codon 61 mutation status, which may cause bias in the distribution of the *KRAS* mutation. Three whole exome sequencing studies conducted mutational screening in all *KRAS* exons and found that the mutations were clustered in the hotspots (29-31). In the current study, mutations were detected in codons 12, 13 and 61 of the *KRAS* gene, and two out of 36 (5.6%) HCCs harbored *KRAS* mutations in codon 61. Therefore, *KRAS* gene mutations may participate in hepatocellular carcinogenesis.

The present study also investigated the hotspot mutations in *NRAS* and *HRAS*, but found no mutation in the two genes. Few studies have focused on the mutation incidence of these two *RAS* family members in Chinese patients with HCC. A whole exome sequencing study identified no mutation in these two genes in a Chinese population (31). Challen *et al* found that the frequency of *NRAS* mutations was 15.8%, but did not identify *HRAS* mutations, in British patients with HCC (32). Taketomi *et al* reported neither *NRAS* nor *HRAS* mutations were detected in Japanese HCC cases (33). Thus, the mutational activation of *NRAS* and *HRAS* genes is an uncommon event in the pathogenesis of HCCs.

*BRAF* mutations can abnormally activate downstream signaling pathways in HCC and act as indicator of cetuximab resistance in patients with colon cancer (34,35). *BRAF* mutations are believed to be rare in HCCs. Previously, no *BRAF* mutations were identified in German and Chinese populations (27,36). However, Colombino *et al* detected that the *BRAF* gene was highly mutated in ~23% of Italian HCC cases (37). In the current series, no *BRAF* mutations were observed, indicating that *BRAF* mutation does not play a major role in abnormal activation of RAS/RAF signaling pathway.

*PIK3CA*, *PIK3R1* and *PTEN* are key genes in the PI3K/PTEN pathway (8). In the current study, it was found that mutations were absent in the three genes. Previously, *PIK3CA* was observed to be frequently mutated in Korean and Italian patients with HCC, with mutation rates of 35.6 and 28%, respectively (15,37). However, Tanaka *et al* did not identify *PIK3CA* mutations in Japanese patients with HCC, and Riener *et al* reported that the *PIK3CA* mutation incidence was 2% in Swiss patients with HCC (38,39). In two studies in Chinese patients with HCC, the mutation rates were 1.6 and 1.1% (36,40), which were similar to those of the present study. The conflicting data may be due to the different genetic backgrounds of the populations, HBV infection status and smaller sample size in the current study. *PIK3R1* mutation has been found to occur infrequently in numerous cancer types, including ovarian and colon cancer (19), and the present study showed a low frequency of alteration of *PIK3R1* in HCC. Inactivation of *PTEN* in HCC may be largely due to frequent loss of heterozygosity of the *PTEN* allele; the frequency was identified to be ≤44.4% (41). Wang *et al* investigated *PTEN* mutations in exons 5 and 8, but failed to detect any (42), which was in agreement with the results of the present study. Mutations in the *PIK3CA*, *PIK3R1* and *PTEN* genes rarely occur in HCC, suggesting that somatic point mutations of these three genes may not play an important role in HCC in the Chinese population. However, further research is necessary to confirm these results in larger sample size.

In summary, the present study investigated the prevalence of *KRAS*, *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and

*PTEN* mutations in 57 hotspot mutations. Two cases of *KRAS* mutation were identified among 36 HCC cases. The findings indicated that point mutations in the *KRAS* gene, but not mutations in the *NRAS*, *HRAS*, *BRAF*, *PIK3CA*, *PIK3R1* and *PTEN* genes, at the somatic level contribute to the abnormal activation of the RAS/RAF and PI3K/PTEN pathways in HCC. Considering the low frequency of key genes in the RAS/RAF and PI3K/PTEN signaling pathways, other mechanisms to activate the RAS/RAF and PI3K/PTEN pathways, such as gene amplification, deletion, and aberrant methylation, may be involved in the development and progression of HCC.

## Acknowledgements

This study was supported by grants from the Key Research Program of the Chinese Academy of Sciences (grant no. KSZD-EW-Z-019), the National Nature Science Foundation (grant nos. 31101261, 81302507 and 81302809), the Ministry of Science and Technology of China (grant no. 2014AA020524), the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (grant nos. 2012KIP308 and 2012KIP515) and the Food Safety Research Center and Key Laboratory of Food Safety Research of INS, SIBS, CAS. Dr. Peizhan Chen was partially supported by the SA-SIBS scholarship program.

## References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. *CA Cancer J Clin* 61: 69-90, 2011.
2. McGlynn KA and London WT: The global epidemiology of hepatocellular carcinoma: present and future. *Clin Liver Dis* 15: 223-243, vii-x, 2011.
3. Owonikoko TK and Khuri FR: Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. *Am Soc Clin Oncol Educ Book*: 2013. doi: 10.1200/EdBook\_AM.2013.33.e395.
4. McCubrey JA, Steelman LS, Abrams SL, *et al*: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. *Leukemia* 22: 708-722, 2008.
5. Downward J: Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* 3: 11-22, 2003.
6. Zheng Y, Li J, Johnson DL and Ou JH: Regulation of hepatitis B virus replication by the ras-mitogen-activated protein kinase signaling pathway. *J Virol* 77: 7707-7712, 2003.
7. Liu H, Xu J, Zhou L, *et al*: Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. *Cancer Res* 71: 7547-7557, 2011.
8. Steelman LS, Chappell WH, Abrams SL, *et al*: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. *Aging (Albany NY)* 3: 192-222, 2011.
9. Fernández-Medarde A and Santos E: Ras in cancer and developmental diseases. *Genes Cancer* 2: 344-358, 2011.
10. Fransén K, Klintonäs M, Osterström A, Dimberg J, Monstein HJ and Söderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. *Carcinogenesis* 25: 527-533, 2004.
11. Libra M, Malaponte G, Navolanic PM, *et al*: Analysis of BRAF mutation in primary and metastatic melanoma. *Cell Cycle* 4: 1382-1384, 2005.
12. Fukushima T, Suzuki S, Mashiko M, *et al*: BRAF mutations in papillary carcinomas of the thyroid. *Oncogene* 22: 6455-6457, 2003.
13. Roymans D and Slegers H: Phosphatidylinositol 3-kinases in tumor progression. *Eur J Biochem* 268: 487-498, 2001.
14. Samuels Y, Wang Z, Bardelli A, *et al*: High frequency of mutations of the PIK3CA gene in human cancers. *Science* 304: 554, 2004.

15. Lee JW, Soung YH, Kim SY, *et al*: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. *Oncogene* 24: 1477-1480, 2005.
16. Shayesteh L, Lu Y, Kuo WL, *et al*: PIK3CA is implicated as an oncogene in ovarian cancer. *Nat Genet* 21: 99-102, 1999.
17. Ligresti G, Militello L, Steelman LS, *et al*: PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. *Cell Cycle* 8: 1352-1358, 2009.
18. Urlick ME, Rudd ML, Godwin AK, Sgroi D, Merino M and Bell DW: PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. *Cancer Res* 71: 4061-4067, 2011.
19. Philp AJ, Campbell IG, Leet C, *et al*: The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. *Cancer Res* 61: 7426-7429, 2001.
20. Stambolic V, Suzuki A, de la Pompa JL, *et al*: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. *Cell* 95: 29-39, 1998.
21. Tamguney T and Stokoe D: New insights into PTEN. *J Cell Sci* 120: 4071-4079, 2007.
22. Chappell WH, Steelman LS, Long JM, *et al*: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget* 2: 135-164, 2011.
23. Llovet JM, Bru C and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 19: 329-338, 1999.
24. Forbes SA, Bindal N, Bamford S, *et al*: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res* 39: D945-D950, 2011.
25. Zhu AX: Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. *Cancer* 112: 250-259, 2008.
26. De La O JP and Murtaugh LC: Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. *Cell Cycle* 8: 1860-1864, 2009.
27. Tannapfel A, Sommerer F, Benicke M, *et al*: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. *Gut* 52: 706-712, 2003.
28. Balschun K, Haag J, Wenke AK, von Schonfels W, Schwarz NT and Rocken C: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. *J Mol Diagn* 13: 436-445, 2011.
29. Fujimoto A, Totoki Y, Abe T, *et al*: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nat Genet* 44: 760-764, 2012.
30. Guichard C, Amadio G, Imbeaud S, *et al*: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nat Genet* 44: 694-698, 2012.
31. Huang J, Deng Q, Wang Q, *et al*: Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. *Nat Genet* 44: 1117-1121, 2012.
32. Challen C, Guo K, Collier JD, Cavanagh D and Bassendine MF: Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. *J Hepatol* 14: 342-346, 1992.
33. Taketomi A, Shirabe K, Muto J, *et al*: A rare point mutation in the Ras oncogene in hepatocellular carcinoma. *Surg Today* 43: 289-292, 2013.
34. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC and Tran E: Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. *BMC Gastroenterol* 3: 19, 2003.
35. Di Nicolantonio F, Martini M, Molinari F, *et al*: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 26: 5705-5712, 2008.
36. Zuo Q, Huang H, Shi M, *et al*: Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. *Anat Rec (Hoboken)* 295: 423-431, 2012.
37. Colombino M, Sperlongano P, Izzo F, *et al*: BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. *Cell Death Dis* 3: e259, 2012.
38. Tanaka Y, Kanai F, Tada M, *et al*: Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. *Oncogene* 25: 2950-2952, 2006.
39. Riener MO, Bawohl M, Clavien PA and Jochum W: Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. *Genes Chromosomes Cancer* 47: 363-367, 2008.
40. Li X, Zhang Q, He W, *et al*: Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population. *Pathol Oncol Res* 18: 57-60, 2012.
41. Bae JJ, Rho JW, Lee TJ, *et al*: Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. *Oncol Rep* 18: 1007-1013, 2007.
42. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J and Li QL: Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. *Hepatol Res* 37: 389-396, 2007.
43. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T and Terada M: Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. *Jpn J Cancer Res* 80: 196-199, 1989.
44. Taniguchi K, Yamada T, Sasaki Y and Kato K: Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. *BMC Cancer* 10: 530, 2010.
45. Tada M, Omata M and Ohto M: Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. *Cancer Res* 50: 1121-1124, 1990.
46. Bose S, Sakhuja P, Bezawada L, *et al*: Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling. *J Gastroenterol Hepatol* 26: 135-144, 2011.
47. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R and Tannapfel A: Frequent k-ras -2 mutations and p16(INK4A) methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. *Br J Cancer* 84: 982-989, 2001.